{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:20:38Z","timestamp":1788520838752,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1007\/s11912-006-0074-9","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T16:05:39Z","timestamp":1180800339000},"page":"448-454","source":"Crossref","is-referenced-by-count":55,"title":["The current treatment of recurrent ovarian cancer"],"prefix":"10.1007","volume":"8","author":[{"given":"Thomas J.","family":"Herzog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"74_CR1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106\u2013130.","journal-title":"CA Cancer J Clin"},{"key":"74_CR2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, et al.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20:248\u2013259.","journal-title":"J Clin Oncol"},{"key":"74_CR3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34\u201343. One of two important papers that report the results of the definitive clinical trials showing the potential advantages for intraperitoneal and maintenance therapy.","journal-title":"N Engl J Med"},{"key":"74_CR4","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","volume":"21","author":"M Markman","year":"2003","unstructured":"Markman M, Liu PY, Wilczynski S, et al.: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxelbased chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003, 21:2460\u20132465 The second of two important papers that report the results of the definitive clinical trials showing the potential advantages for intraperitoneal and maintenance therapy.","journal-title":"J Clin Oncol"},{"key":"74_CR5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","volume":"9","author":"M Markman","year":"1991","unstructured":"Markman M, Rothman R, Hakes T, et al.: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991, 9:389\u2013393.","journal-title":"J Clin Oncol"},{"key":"74_CR6","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1158\/1078-0432.CCR-04-0683","volume":"10","author":"TJ Herzog","year":"2004","unstructured":"Herzog TJ: Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004, 10:7439\u20137449. This paper includes a thorough discussion of treatment options in recurrent ovarian cancer and discusses the important concept of treating primary and secondary platinum-resistant patients until disease progression.","journal-title":"Clin Cancer Res"},{"key":"74_CR7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/annonc\/mdl079","volume":"17","author":"J Sehouli","year":"2006","unstructured":"Sehouli J, Oskay-Ozcelik G, Kuhne J, et al.: Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol 2006, 17:957\u2013961.","journal-title":"Ann Oncol"},{"key":"74_CR8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1634\/theoncologist.10-3-205","volume":"10","author":"PG Rose","year":"2005","unstructured":"Rose PG: Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005, 10:205\u2013214.","journal-title":"Oncologist"},{"issue":"Suppl 13","key":"74_CR9","first-page":"91","volume":"31","author":"M Markman","year":"2005","unstructured":"Markman M, Gordon AN, McGuire WP, Muggia FM: Liposomal anthracycline treatment for ovarian cancer. Semin Oncol 2005, 31(Suppl 13):91\u2013105.","journal-title":"Semin Oncol"},{"key":"74_CR10","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"N Gordon","year":"2001","unstructured":"Gordon N, Fleagle JT, Guthrie D, et al.: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19:3312\u20133322.","journal-title":"J Clin Oncol"},{"key":"74_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","volume":"95","author":"AN Gordon","year":"2004","unstructured":"Gordon AN, Tonda M, Sun S, et al.: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004, 95:1\u20138.","journal-title":"Gynecol Oncol"},{"key":"74_CR12","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.1996.14.5.1552","volume":"14","author":"AP Kudelka","year":"1996","unstructured":"Kudelka AP, Tresukosol D, Edwards CL, et al.: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996, 14:1552\u20131557.","journal-title":"J Clin Oncol"},{"key":"74_CR13","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","volume":"14","author":"GJ Creemers","year":"1996","unstructured":"Creemers GJ, Bolis G, Gore M, et al.: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996, 14:3056\u20133061.","journal-title":"J Clin Oncol"},{"key":"74_CR14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/gyno.1997.4787","volume":"66","author":"EM Swisher","year":"1997","unstructured":"Swisher EM, Mutch DG, Rader JS, et al.: Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997, 66:480\u2013486.","journal-title":"Gynecol Oncol"},{"key":"74_CR15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1006\/gyno.2001.6365","volume":"83","author":"M Rodriguez","year":"2001","unstructured":"Rodriguez M, Rose PG: Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 2001, 83:257\u2013262.","journal-title":"Gynecol Oncol"},{"key":"74_CR16","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0090-8258(03)00470-0","volume":"90","author":"RT Morris","year":"2003","unstructured":"Morris RT: Weekly topotecan in the management of ovarian cancer. Gynecol Oncol 2003, 90:S34-S38.","journal-title":"Gynecol Oncol"},{"key":"74_CR17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ygyno.2004.08.026","volume":"95","author":"SM Bhoola","year":"2004","unstructured":"Bhoola SM, Coleman RL, Herzog T, et al.: Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol 2004, 95:564\u2013569.","journal-title":"Gynecol Oncol"},{"key":"74_CR18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ygyno.2004.09.005","volume":"95","author":"T Levy","year":"2004","unstructured":"Levy T, Inbar M, Menczer J, et al.: Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 2004, 95:686\u2013690.","journal-title":"Gynecol Oncol"},{"key":"74_CR19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0090-8258(02)00021-5","volume":"88","author":"J Brown","year":"2003","unstructured":"Brown J, Peters W III, Rettenmaier M, et al.: Three consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol 2003, 88:136\u2013140.","journal-title":"Gynecol Oncol"},{"key":"74_CR20","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/cncr.11690","volume":"98","author":"D Miller","year":"2003","unstructured":"Miller D, Blessing J, Lentz S, McMeekin DS: Phase II evaluation of three-day topotecan in recurrent platinum sensitive ovarian cancer. Cancer 2003, 98:1664\u20131669.","journal-title":"Cancer"},{"key":"74_CR21","doi-asserted-by":"crossref","unstructured":"Herzog TJ, Powell MA, Rader JS, et al.: Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol 2006 Jun 14, [Epub ahead of print].","DOI":"10.1016\/j.ygyno.2006.04.014"},{"issue":"Suppl 6","key":"74_CR22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00001813-199512006-00010","volume":"6","author":"B Lund","year":"1995","unstructured":"Lund B, Hansen OP, Neijt JP, et al.: Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs 1995, 6(Suppl 6):61\u201362.","journal-title":"Anticancer Drugs"},{"key":"74_CR23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0090-8258(03)00399-8","volume":"90","author":"M Markman","year":"2003","unstructured":"Markman M, Webster K, Zanotti K, et al.: Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 2003, 90:593\u2013596.","journal-title":"Gynecol Oncol"},{"key":"74_CR24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","volume":"63","author":"JD Shapiro","year":"1996","unstructured":"Shapiro JD, Millward MJ, Rischin D, et al.: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996, 63:89\u201393.","journal-title":"Gynecol Oncol"},{"key":"74_CR25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.2002.6850","volume":"88","author":"PG Rose","year":"2003","unstructured":"Rose PG, Mossbruger K, Fusco N, et al.: Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003, 88:17\u201321.","journal-title":"Gynecol Oncol"},{"key":"74_CR26","doi-asserted-by":"crossref","unstructured":"Brewer CA, Blessing JA, Nagourney RA, et al.: Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006 Apr 24 [Epub ahead of print].","DOI":"10.1016\/j.ygyno.2006.03.018"},{"key":"74_CR27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","volume":"88","author":"PG Rose","year":"2003","unstructured":"Rose PG, Blessing JA, Ball HG, et al.: Phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2003, 88:130\u2013135.","journal-title":"Gynecol Oncol"},{"key":"74_CR28","first-page":"275","volume":"14","author":"JC Schink","year":"1995","unstructured":"Schink JC, Harris LS, Grosen ER, et al.: Altretamine (Hexalin) An effective salvage chemotherapy after paclitaxel (Taxol) in women with recurrent platinum resistant ovarian cancer [abstract]. Proc ASCO 1995, 14:275.","journal-title":"Proc ASCO"},{"key":"74_CR29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1998.5016","volume":"69","author":"M Markman","year":"1998","unstructured":"Markman M, Blessing JA, Moore D, et al.: Altretamine (hexamethylmelamine) in platinum-resistant and platinumrefractory ovarian cancer: a Gynecologic Oncology Group Phase II trial. Gynecol Oncol 1998, 69:226\u2013229.","journal-title":"Gynecol Oncol"},{"key":"74_CR30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","volume":"16","author":"PG Rose","year":"1998","unstructured":"Rose PG, Blessing JA, Mayer AR, et al.: Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinomas: A Gynecologic Oncology Group Study. J Clin Oncol 1998, 16:405\u2013410.","journal-title":"J Clin Oncol"},{"key":"74_CR31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1200\/JCO.1992.10.2.243","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Hakes T, Reichman B, et al.: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 1992, 10:243\u2013248.","journal-title":"J Clin Oncol"},{"key":"74_CR32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1006\/gyno.1996.0181","volume":"62","author":"M Markman","year":"1996","unstructured":"Markman M, Iseminger KA, Hatch KD, et al.: Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group ancillary report. Gynecol Oncol 1996, 62:4\u20136.","journal-title":"Gynecol Oncol"},{"key":"74_CR33","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.1996.14.9.2546","volume":"14","author":"E Bajetta","year":"1996","unstructured":"Bajetta E, Di Leo A, Biganzoli L, et al.: Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996, 14:2546\u20132551.","journal-title":"J Clin Oncol"},{"key":"74_CR34","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MK Parmar","year":"2003","unstructured":"Parmar MK, Ledermann JA, Colombo N, et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet 2003, 361:2099\u20132106. This study introduced the concept of treatment with platinum-based doublets in platinum-sensitive recurrent ovarian cancer and showed an overall survival advantage for those treated with doublets.","journal-title":"Lancet"},{"key":"74_CR35","first-page":"449","volume":"23","author":"J Pfisterer","year":"2004","unstructured":"Pfisterer J, Plante M, Vergote I, et al.: Gemcitabine\/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG [abstract]. Proc ASCO 2004, 23:449. This study further reinforces the concept of treatment with a platinum-based doublet in patients with recurrent ovarian cancer, but only a progression-free advantage, rather than an overall survival advantage, was shown.","journal-title":"Proc ASCO"},{"key":"74_CR36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ygyno.2004.03.023","volume":"93","author":"M Markman","year":"2004","unstructured":"Markman M, Webster K, Zanotti K, et al.: Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol 2004, 93:699\u2013701.","journal-title":"Gynecol Oncol"},{"key":"74_CR37","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1200\/JCO.1991.9.10.1801","volume":"9","author":"M Markman","year":"1991","unstructured":"Markman M, Reichman B, Hakes T, et al.: Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991, 9:1801\u20131805.","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"74_CR38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminoncol.2004.10.015","volume":"31","author":"C Aghajanian","year":"2004","unstructured":"Aghajanian C: Clinical update: novel targets in gynecologic malignancies. Semin Oncol 2004, 31(Suppl 16):22\u201326.","journal-title":"Semin Oncol"},{"key":"74_CR39","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1517\/13543784.14.8.1047","volume":"14","author":"KD Tew","year":"2005","unstructured":"Tew KD: TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs 2005, 14:1047\u20131054.","journal-title":"Expert Opin Investig Drugs"},{"key":"74_CR40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA, Darcy KM, Clarke-Pearson D, et al.: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:283\u2013290.","journal-title":"J Clin Oncol"},{"key":"74_CR41","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/S0959-8049(03)00490-8","volume":"39","author":"M D\u2019Incalci","year":"2003","unstructured":"D\u2019Incalci M, Colombo T, Ubezio P, et al.: (2003) The combination of Yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003, 39:1920\u20131926.","journal-title":"Eur J Cancer"},{"key":"74_CR42","first-page":"457s","volume":"23","author":"RA Burger","year":"2005","unstructured":"Burger RA, Sill M, Monk B, et al.: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study [abstract]. Proc ASCO 2005, 23:457s.","journal-title":"Proc ASCO"},{"key":"74_CR43","first-page":"455s","volume":"23","author":"AA Garcia","year":"2005","unstructured":"Garcia AA, Oza AM, Hirte H, et al.: Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial [abstract]. Proc ASCO 2005, 23:455s.","journal-title":"Proc ASCO"},{"key":"74_CR44","first-page":"5006","volume":"24","author":"S Cannistra","year":"2006","unstructured":"Cannistra S, Matulonis U, Penson R, et al.: Bevacizumab in patients with advanced platinum-resistant ovarian cancer [abstract]. Proc ASCO 2006, 24:5006.","journal-title":"Proc ASCO"},{"key":"74_CR45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21969","volume":"107","author":"JD Wright","year":"2006","unstructured":"Wright JD, Hagemann A, Rader JS, et al.: Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006, 107:83\u201389.","journal-title":"Cancer"},{"key":"74_CR46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0090-8258(88)90262-4","volume":"31","author":"KC Podratz","year":"1998","unstructured":"Podratz KC, Schray MF, Wieand HS, et al.: Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol 1998, 31:9\u201324.","journal-title":"Gynecol Oncol"},{"key":"74_CR47","doi-asserted-by":"crossref","unstructured":"Hoskins WJ, Rubin SC, Dulaney E, et al.: Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 134:365\u2013371.","DOI":"10.1016\/0090-8258(89)90175-3"},{"key":"74_CR48","first-page":"645","volume":"18","author":"WA McCreath","year":"2004","unstructured":"McCreath WA, Chi DS: Surgical cytoreduction in ovarian cancer. Oncology 2004, 18:645\u2013653.","journal-title":"Oncology"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-006-0074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-006-0074-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-006-0074-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:31:30Z","timestamp":1559435490000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-006-0074-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1007\/s11912-006-0074-9","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}